V1b receptors: new probes for therapy.
Arban
Roberto
R
Department of Biology, GlaxoSmithKline Group, Psychiatry Centre of Excellence for Drug Discovery, Medicines Research Centre, Via Fleming, 4, 37135 Verona, Italy. Roberto.2.Arban@gsk.com
D000818:Animals; D001127:Arginine Vasopressin / Q000378:metabolism; D001921:Brain / Q000502:physiology; D006801:Humans; D007211:Indoles; D011759:Pyrrolidines; D051381:Rats; D017483:Receptors, Vasopressin / Q000819:agonists* / Q000145:classification / Q000502:physiology; D011994:Recombinant Proteins / Q000378:metabolism; D014667:Vasopressins / Q000502:physiology*
C456029:1-(5-chloro-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl)-4-hydroxy-N,N-dimethyl-2-pyrrolidinecarboxamide; D007211:Indoles; D011759:Pyrrolidines; D017483:Receptors, Vasopressin; D011994:Recombinant Proteins; D014667:Vasopressins; D001127:Arginine Vasopressin